Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ATP8B1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ATP8B1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ATP8B1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ATP8B1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ATP8B1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/ATP8B1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ATP8B1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ATP8B1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ATP8B1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ATP8B1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:012003231 | Oral cavity | NEOLP | regulation of plasma membrane bounded cell projection assembly | 33/2005 | 186/18723 | 2.50e-03 | 1.58e-02 | 33 |
GO:006049131 | Oral cavity | NEOLP | regulation of cell projection assembly | 33/2005 | 188/18723 | 2.98e-03 | 1.82e-02 | 33 |
GO:19037291 | Oral cavity | NEOLP | regulation of plasma membrane organization | 6/2005 | 15/18723 | 3.18e-03 | 1.91e-02 | 6 |
GO:000700911 | Oral cavity | NEOLP | plasma membrane organization | 26/2005 | 142/18723 | 4.41e-03 | 2.48e-02 | 26 |
GO:001574811 | Oral cavity | NEOLP | organophosphate ester transport | 25/2005 | 140/18723 | 7.16e-03 | 3.63e-02 | 25 |
GO:00604919 | Prostate | BPH | regulation of cell projection assembly | 51/3107 | 188/18723 | 1.73e-04 | 1.48e-03 | 51 |
GO:012003210 | Prostate | BPH | regulation of plasma membrane bounded cell projection assembly | 50/3107 | 186/18723 | 2.53e-04 | 2.00e-03 | 50 |
GO:00070306 | Prostate | BPH | Golgi organization | 39/3107 | 157/18723 | 5.20e-03 | 2.43e-02 | 39 |
GO:006049115 | Prostate | Tumor | regulation of cell projection assembly | 52/3246 | 188/18723 | 2.71e-04 | 2.24e-03 | 52 |
GO:012003215 | Prostate | Tumor | regulation of plasma membrane bounded cell projection assembly | 51/3246 | 186/18723 | 3.87e-04 | 2.99e-03 | 51 |
GO:000703013 | Prostate | Tumor | Golgi organization | 40/3246 | 157/18723 | 6.33e-03 | 2.90e-02 | 40 |
GO:00070093 | Prostate | Tumor | plasma membrane organization | 36/3246 | 142/18723 | 1.00e-02 | 4.20e-02 | 36 |
GO:00325285 | Stomach | GC | microvillus organization | 13/1159 | 24/18723 | 2.41e-10 | 3.75e-08 | 13 |
GO:00325306 | Stomach | GC | regulation of microvillus organization | 8/1159 | 13/18723 | 2.05e-07 | 1.12e-05 | 8 |
GO:00300335 | Stomach | GC | microvillus assembly | 8/1159 | 16/18723 | 1.73e-06 | 7.78e-05 | 8 |
GO:00601192 | Stomach | GC | inner ear receptor cell development | 8/1159 | 45/18723 | 5.84e-03 | 4.44e-02 | 8 |
GO:003252811 | Stomach | CAG with IM | microvillus organization | 9/1050 | 24/18723 | 3.22e-06 | 1.29e-04 | 9 |
GO:003253011 | Stomach | CAG with IM | regulation of microvillus organization | 6/1050 | 13/18723 | 3.74e-05 | 1.02e-03 | 6 |
GO:003003311 | Stomach | CAG with IM | microvillus assembly | 6/1050 | 16/18723 | 1.51e-04 | 2.97e-03 | 6 |
GO:006011911 | Stomach | CAG with IM | inner ear receptor cell development | 8/1050 | 45/18723 | 3.22e-03 | 2.96e-02 | 8 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP8B1 | SNV | Missense_Mutation | novel | c.794N>T | p.Cys265Phe | p.C265F | O43520 | protein_coding | deleterious(0) | possibly_damaging(0.822) | TCGA-A2-A25D-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | SD |
ATP8B1 | SNV | Missense_Mutation | | c.2584N>T | p.Ala862Ser | p.A862S | O43520 | protein_coding | tolerated(0.12) | benign(0.178) | TCGA-A7-A0CJ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATP8B1 | SNV | Missense_Mutation | novel | c.88N>A | p.Glu30Lys | p.E30K | O43520 | protein_coding | tolerated_low_confidence(0.17) | benign(0.339) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ATP8B1 | SNV | Missense_Mutation | novel | c.2224A>G | p.Ile742Val | p.I742V | O43520 | protein_coding | tolerated(0.06) | benign(0.298) | TCGA-BH-A1FU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ATP8B1 | SNV | Missense_Mutation | novel | c.1663G>A | p.Glu555Lys | p.E555K | O43520 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD |
ATP8B1 | insertion | Frame_Shift_Ins | novel | c.225_226insTTCTCCTGCCTCAGCCTCC | p.Gln76PhefsTer19 | p.Q76Ffs*19 | O43520 | protein_coding | | | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
ATP8B1 | insertion | Nonsense_Mutation | novel | c.3405_3406insATCTGAATACAATCAATTTCCATTAGAAAGAAGGAGAGAGTAGAGG | p.Ala1136IlefsTer2 | p.A1136Ifs*2 | O43520 | protein_coding | | | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
ATP8B1 | SNV | Missense_Mutation | novel | c.3418N>A | p.Leu1140Met | p.L1140M | O43520 | protein_coding | tolerated(0.21) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ATP8B1 | SNV | Missense_Mutation | novel | c.3190N>C | p.Glu1064Gln | p.E1064Q | O43520 | protein_coding | tolerated(0.25) | probably_damaging(0.969) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
ATP8B1 | SNV | Missense_Mutation | | c.46N>G | p.Gln16Glu | p.Q16E | O43520 | protein_coding | tolerated_low_confidence(0.16) | benign(0.001) | TCGA-VS-A9UY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |